PIPs

Quote






Private actions have no harbor for completely ommitting risk factors that end up coming to fruition. The only real harbor is to buy an expensive primary residence. At least that pretty much assures there will always be a home if there is enough money to pay things like property taxes and electric bills.
 






Any one who says they like working here or the environment is good has not been here very long. During the NSM TR asked people who had been with dndn less than 1 yr to stand Roughly 70% of the commercial org stood. So keep watching newbies.

I understand why these people love working at Dendreon. The company is paying insane amounts of money to attrack people and Management is saying a lot of good stuff. The problem is nothing has really changed.

Example: during the NSM there was a lot of talk about a new sales process. It went something like this:

1) Develop clinical conviction
2) Remove barriers to access
3) mobilze e systematic patient id

Then there was a lot of chatter about "-- we must understand where the customer is in the sales process." This sounds good, right? Sure it does. Problems is this is not the reality. Many want to skip step 2 and go from step 1 to step 3. Hell, some would just rather you bring in the contract and forget steps 1 and 2. Whats more is as soon as we got back in the field we had another soft week and are being directed to go chase enrollments or else you suck as a rep.

I've not began to touch on the huge influx of people who are Amgen drones. Of course if you are from Amgen you probably don't see a problem here. But if you are not then you are beginning to feel like your career options might be very limited at DNDN because these folks are loyal to one another not because of performance but because of ego stroking and ball licking.

Did anyone read the email that "E" sent to TR right around Christmas? I'm sure he didnt mean to reply to all but he basically gave him a BJ over email for all to see.
 






Anonymous said:
Private actions have no harbor for completely ommitting risk factors that end up coming to fruition. The only real harbor is to buy an expensive primary residence. At least that pretty much assures there will always be a home if there is enough money to pay things like property taxes and electric bills.
Click to expand...

It probably behooves some to try to salvage as much of a wrecked life as possible.
 






Anonymous said:
Any one who says they like working here or the environment is good has not been here very long. During the NSM TR asked people who had been with dndn less than 1 yr to stand Roughly 70% of the commercial org stood. So keep watching newbies.

I understand why these people love working at Dendreon. The company is paying insane amounts of money to attrack people and Management is saying a lot of good stuff. The problem is nothing has really changed.

Example: during the NSM there was a lot of talk about a new sales process. It went something like this:

1) Develop clinical conviction
2) Remove barriers to access
3) mobilze e systematic patient id

Then there was a lot of chatter about "-- we must understand where the customer is in the sales process." This sounds good, right? Sure it does. Problems is this is not the reality. Many want to skip step 2 and go from step 1 to step 3. Hell, some would just rather you bring in the contract and forget steps 1 and 2. Whats more is as soon as we got back in the field we had another soft week and are being directed to go chase enrollments or else you suck as a rep.

I've not began to touch on the huge influx of people who are Amgen drones. Of course if you are from Amgen you probably don't see a problem here. But if you are not then you are beginning to feel like your career options might be very limited at DNDN because these folks are loyal to one another not because of performance but because of ego stroking and ball licking.

Did anyone read the email that "E" sent to TR right around Christmas? I'm sure he didnt mean to reply to all but he basically gave him a BJ over email for all to see.
Click to expand...

You hit the nail on the head! Couldn't have said it better. Who the hell is EG anyway? Saw that email and almost puked. That's the "culture" here now.
 






I have been here three years and I think it is a great place to work. I think it always makes sense to "understand where the customer is in the sales process." Why would you not want to know that? I also had a strong week in the field following the NSM. In my opinion, the NSM went fine.
 


















The "culture" at Dendreon is better than most companies I have worked at. I fully agree with post #86 and the NSM went fine and I am looking forward to 2013 with my personal expectations of nice growth in provenge revenues and continued declines in Zytiga sales - something that actually happened in Q4 2012 with Zytiga revenues down 16% in the U.S..
 






Anonymous said:
I fully agree with post #86 and the NSM went fine and I am looking forward to 2013 with my personal expectations of nice growth in provenge revenues and continued declines in Zytiga sales - something that actually happened in Q4 2012 with Zytiga revenues down 16% in the U.S..
Click to expand...

You are the writer of post 86. Of course you agree.
 






Okay poster 89. Time for a reality check. Zytiga sales ain't on the decline because of Provenge and 5% sequential growth is nothing to cheer over. It is hardly a breakout trend. 81M is well within the normal up and down trends we've seen over the last several quarters. That means Q1-13 results can be anybody's guess +\-.

The way I see it, JJ and the crew is playing a pipe to you ship full of rats and you like the song because you are paid well and had a nice meeting in a posh hotel.

Look at it this way, 5% sequential growth equates to 41 more patients in q4 than q3.
(3.9M /93k=41). 3.9m is diff btw q3 and q4 sales divided by price of treatment gives you number of patients represented by the growth --41

Is that anything to get excited about? That means of the 140 people in the field including those in the scg, less than 30 percent of you grew your business by 1 patient. I'd be very worried if q1 looks anything like Q4. This signals, IMHO, that DNDN could exist with 25 reps and an scg group.
 






Anonymous said:
Okay poster 89. Time for a reality check. Zytiga sales ain't on the decline because of Provenge and 5% sequential growth is nothing to cheer over. It is hardly a breakout trend. 81M is well within the normal up and down trends we've seen over the last several quarters. That means Q1-13 results can be anybody's guess +\-.

The way I see it, JJ and the crew is playing a pipe to you ship full of rats and you like the song because you are paid well and had a nice meeting in a posh hotel.

Look at it this way, 5% sequential growth equates to 41 more patients in q4 than q3.
(3.9M /93k=41). 3.9m is diff btw q3 and q4 sales divided by price of treatment gives you number of patients represented by the growth --41

Is that anything to get excited about? That means of the 140 people in the field including those in the scg, less than 30 percent of you grew your business by 1 patient. I'd be very worried if q1 looks anything like Q4. This signals, IMHO, that DNDN could exist with 25 reps and an scg group.
Click to expand...

Dude, I love your posts but you give post 89 guy too much credit. He is a straw man. Even when you realize that, please continue your informative posts that give a glimpse into the bowels of the company.
 






Anonymous said:
That means Q1-13 results can be anybody's guess +\-.
Click to expand...

It's TRULY anybody's guess. Investors are hesitant because no one knows how much has been accelerated into q4 2012 from q1 2013. Everyone learned from last year's pre-announcement that selective disclosure is a concept they don't understand. Laws? What laws?
 






Anonymous said:
It's TRULY anybody's guess. Investors are hesitant because no one knows how much has been accelerated into q4 2012 from q1 2013. Everyone learned from last year's pre-announcement that selective disclosure is a concept they don't understand. Laws? What laws?
Click to expand...

Lasy year we had to wait until February 27, 2012 to find out the whole story. This is what Greg Schiffman told us that day:

"As we indicated in January, our December numbers were higher than expected and we believe our customers accelerated some January business into December probably to the tune of $2 million to $3 million."

Unfortunately, none of us imagined that the "higher than expected" quarter was helped out by 2-3 million of revenues accelerated from the 1st quarter.

Now we know these yearly pre-announcements mean absolutely nothing because a material number may be told to us at the earnings call that tells us who much was accelerated from the 1st quarter to the 4th quarter.

If there are any accountants out there, I would really like to know what "$2 million to $3 million" means? Would a CFO know the exact amount or at least within a much tighter range than $2 to $3 million? It could have been $2.999M and he gets the benefit of saying $2 to $3 million. If he knew it to be $2.222 million would he say $2 to $3 million?
 






Anonymous said:
Okay poster 89. Time for a reality check. Zytiga sales ain't on the decline because of Provenge and 5% sequential growth is nothing to cheer over. It is hardly a breakout trend. 81M is well within the normal up and down trends we've seen over the last several quarters. That means Q1-13 results can be anybody's guess +\-.

The way I see it, JJ and the crew is playing a pipe to you ship full of rats and you like the song because you are paid well and had a nice meeting in a posh hotel.

Look at it this way, 5% sequential growth equates to 41 more patients in q4 than q3.
(3.9M /93k=41). 3.9m is diff btw q3 and q4 sales divided by price of treatment gives you number of patients represented by the growth --41

Is that anything to get excited about? That means of the 140 people in the field including those in the scg, less than 30 percent of you grew your business by 1 patient. I'd be very worried if q1 looks anything like Q4. This signals, IMHO, that DNDN could exist with 25 reps and an scg group.
Click to expand...

Mckinsey and Associates are busy at work as we speak on hammering out what the new force will look like. I was under the assumption that about 40 reps nationwide would be kept but didnt take into account all the bloating that took place with initiation of the SCG group. Sadly this group has ZERO impact in my area but I understand in the other parts of the nation they are making headway with selling the spread in the large LUGPAs. Word is that end of Q2 will be the day of reckoning. Don't shoot the messenger. If your not "in" with the AMGN/JNJ ass kissing group though, forget about being around here when the hammer drops.

Everyone is doing the right thing by looking and leaving. We will be operating with a skeleton crew of newbies with little to no experience in the Onc space by the end of Q1.
 






Zytiga sales were down 16% in Q4 and Provenge sales were up 5%. Unlike most of the posters here, I actually work at Dendreon. Our new CEO is honest and does not play games with reported results. I have witnessed first hand a strong trend of MDs switching from Zytiga to Provenge. The Docs do not like all the time they need to spend monitoring patients for potential severe adverse side effects of Zytiga. With Provenge there are no adverse side effects for them to monitor, so it is easier for the docs to treat with Provenge. In addition the docs are paid by the insurers $6,000 for every patient they treat with Provenge. For Zytiga, since it is a pill, the docs are not paid anything for providing the drug to patients. I fully expect good sales growth for Provenge to continue in the long-term future, with Provenge continuing to gain market share. We are continuing to add new sales territories to meet this long term rise in demand for Provenge.
 






The above posts regarding a reduction in sales positions at Dendreon is completely untrue. I work at HR at Dendreon and we are currently expanding our salesforce to meet increased product demand. Expansion of our salesforce is an integral part of our long-term strategic plan.
 






Rply to 94: it's hard to get much tighter than 2-3 M. In fact that pretty tight when you consider the therapy cost 93k. That equates to 21-32 patients treated nationwide.

Hey! That's almost the number of patients the company grew by in Q4 which is to say that's not a lot.
 






The Zytiga reps are jumping ship like mad following the 16% sales decline in Q4. J&J is planning a major reduction in salesforce given the strong decrease in demand for their product. Many Zytiga reps are applying for positions at Dendreon I think you have your facts confused, McKinsey & Co. (a McKinsey & Associates does not exist) has been retained by J&J to assist them in strategic planning given the strong decline in the demand for Zytiga.

Here is the correct name for McKinsey & Co.:

http://www.mckinsey.com/
 






All I'm saying is that folks on the dndn farm point to Zytiga's decline as if Provenge was the cause. If that were true dndn would have seen significantly more growth; certainly more than 41 patients. Do you disagree?
 






Top Bottom
Back
Quote